Eva Wesley

Bioprinting, once hailed for its potential to print human organs and tissues, took a backseat after the pandemic. However, with an estimated market value of $1.44 billion in 2024, it’s poised for growth, driven by companies like Swedish Cellnik and Regemat. In Spain, Regemat is a key player, focusing on personalized medicine and pharmaceutical applications. 0 SHARES

Laminar Pharma, founded by Professor Pablo Vicente Escribá, seeks to raise €7 million for its drug trial, LAM561, targeting glioblastoma. With phase III trials underway in 18 hospitals, 124 out of 140 planned patients have participated. Negotiations with pharmaceutical companies are ongoing for licensing the drug, aiming for a deal above €10 million, preferably with a European company.

Eli Lilly’s first-quarter results exceeded expectations, with a $8.77 billion turnover, a 26% year-on-year growth, and $2.24 billion net income, 67% higher than in 2023. Strong sales of antidiabetic drugs like Mounjaro, Jardiance, and Zepbound, along with the oncological treatment Verzenio, contributed to this growth. The company plans to increase its 2024 objectives by $2 billion. 0 SHARES

Berenberg has slashed Grifols’ target price by 23% to 19.8 euros due to higher-than-expected net debt. Despite this, Berenberg remains optimistic about Grifols’ potential, estimating a 134% upside from the current price. Grifols recently announced a private placement of €1 billion in senior secured bonds, intending to use the funds to pay off unsecured bonds due in 2025. 0 SHARES

Novo Nordisk sees substantial growth, reporting a 28% increase in profits to €3.4 billion in Q1 2024, with operating profits up 27% to €4.27 billion. This surge is driven by sales of diabetes drugs Ozempic and Wegovy, leading to a 22% rise in net sales to €8.76 billion. The company raises its 2024 forecasts, aiming for significant profit and sales growth.

The pharmaceutical industry sees a surge in R&D investment, reaching $145.5 billion last year, 4.5% higher than drug launch budgets in 2022.

Zolgensma, Novartis’ gene therapy for SMA, remains the world’s most expensive medicine, priced between $1.2 million and $2.1 million per dose. Despite its high cost, it’s justified by its transformative impact. The therapy has generated $5.2 billion globally and, while expensive, experts consider its price reasonable given its effectiveness and the complexities of gene therapy production.

Boehringer Ingelheim Spain significantly increased its R&D&I investment to 62.7 million euros, up 36% from the previous year, representing 11.5% of net sales. Their human health division focuses on six therapeutic areas, while the animal health division offers vaccines and treatments. The company plans to allocate 93.4 million euros for a new production platform and has made substantial investments in production plants. 0 SHARES

Reig Jofre reported a 15% drop in profits in the first quarter of 2024, attributed to the absence of a biosimilar development milestone.

Sanofi acquires 4.9% of Novavax shares for $70 million, doubling the latter’s valuation to around $1.4 billion. This investment is part of a co-exclusive licensing agreement for joint marketing of Covid-19 vaccines with flu vaccines. Novavax’s first-quarter revenue increased by 16% to $94 million, while losses decreased by 49.6%. 0 SHARES